Biotech: Recalling Its Growing Pains and Celebrating Its Maturity

Abstract

Genetic Engineering & Biotechnology NewsVol. 41, No. 10 CommentaryBiotech: Recalling Its Growing Pains and Celebrating Its MaturityThe commercialization of bioscience has been realizing our hopes, as expected, but in unexpected waysRobert S. Langer, ScDRobert S. Langer, ScDRobert S. Langer, ScD, is the David H. Koch Institute Professor at MIT. Langer has written more than 1,500 articles and has over 1,400 issued and pending patents worldwide. The patents have been licensed or sublicensed to over 400 pharmaceutical, chemical, biotech, and medical device companies. He is the most cited engineer in history (h-index 293 with over 351,000 citations according to Google Scholar).Search for more papers by this authorPublished Online:6 Oct 2021https://doi.org/10.1089/gen.41.10.17AboutSectionsView articleView Full TextPDF/EPUB Permissions & CitationsPermissionsDownload CitationsTrack CitationsAdd to favorites Back To Publication ShareShare onFacebookTwitterLinked InRedditEmail View article"Biotech: Recalling Its Growing Pains and Celebrating Its Maturity." Genetic Engineering & Biotechnology News, 41(10), p. 52FiguresReferencesRelatedDetails Volume 41Issue 10Oct 2021 Information© 2021 by GEN PublishingTo cite this article:Robert S. Langer, ScD.Biotech: Recalling Its Growing Pains and Celebrating Its Maturity.Genetic Engineering & Biotechnology News.Oct 2021.52-52.http://doi.org/10.1089/gen.41.10.17Published in Volume: 41 Issue 10: October 6, 2021PDF download